Pharmacelsus, Germany´s market-leading early stage CRO, plans, organizes and realizes customized preclinical studies for more than 20 years. Our assays meet national and international regulatory demands while using our unique consultative approach to serve more than 120+ satisfied customers who rely on our expertise, experience and passion for science.
The Pharmacelsus portfolio covers the complete drug discovery and development testing program for small molecules and peptides in vitro, in vivo, ex vivo as well as G(C)LP and non-GLP bioanalysis. Structural, physicochemical and functional characterization of Biopharmaceuticals (e.g. Antibodies, ADCs, etc.) complements our comprehensive portfolio.